Case-Based Reasoning in Rare Multisystem Clinical Presentations

Abstract

Rare multisystem clinical presentations pose considerable diagnostic and therapeutic challenges due to their complex, heterogeneous manifestations and limited prevalence. Case-based reasoning (CBR) has emerged as a robust cognitive and practical approach, leveraging clinician experience and documented case repositories to aid in the recognition, diagnosis, and management of such conditions. This article synthesizes current evidence on the role of CBR in rare multisystem disorders, emphasizing epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, management, and recent advancements. The discussion integrates guideline recommendations and practical clinical insights to support healthcare professionals in navigating these intricate clinical scenarios.

Introduction

Multisystem diseases with rare presentations often challenge even experienced clinicians, given their atypical symptomatology and the paucity of established management pathways. These cases typically involve simultaneous or sequential involvement of multiple organ systems and may mimic more common disorders, leading to diagnostic delay or error. Case-based reasoning, a method that applies knowledge from previously encountered cases to new clinical scenarios, has gained traction as a tool to bridge knowledge gaps, foster pattern recognition, and support evidence-based practice in rare diseases. This review delineates the application of CBR in rare multisystem clinical presentations, aiming to inform and enhance clinical decision-making for healthcare professionals.

Epidemiology / Disease Burden

Rare multisystem disorders, by definition, have a low prevalence, often affecting fewer than 5 in 10,000 individuals. Collectively, however, rare diseases impact an estimated 350 million people globally, with a significant proportion presenting with multisystem involvement. The true burden is likely underappreciated due to diagnostic challenges, underreporting, and misclassification. Disorders such as systemic vasculitides, mitochondrial cytopathies, and certain inherited metabolic syndromes exemplify this group. The rarity and clinical heterogeneity hinder the development of large-scale studies, resulting in a reliance on case reports and series, which further underscores the value of CBR for both research and practice.

Pathophysiology

The pathophysiology of rare multisystem diseases is often rooted in complex genetic, immunological, or metabolic abnormalities. Mechanisms may include autoimmunity, mitochondrial dysfunction, aberrant protein folding, or multisystemic inflammation. For example, diseases such as systemic lupus erythematosus (SLE) involve immune dysregulation leading to widespread tissue damage, while mitochondrial encephalomyopathies result from defects in oxidative phosphorylation affecting high-energy-demand organs. Understanding these mechanisms is essential for recognizing subtle clinical cues and tailoring mechanistic therapies, highlighting the practical value of CBR in synthesizing mechanistic insights from diverse case experiences.

Risk Factors

Risk factors for rare multisystem conditions are often multifactorial, encompassing genetic predisposition, environmental exposures, and in some cases, epigenetic modifications. Family history, consanguinity, and specific ethnic backgrounds may heighten risk for certain inherited disorders. Immunological triggers and infectious agents have been implicated in some multisystem autoimmune syndromes. Recognition of risk factors through CBR allows clinicians to stratify patients with non-specific presentations, prompting earlier consideration of rare diagnoses.

Clinical Features

Clinical presentations are characteristically diverse and may involve combinations of constitutional symptoms (fever, weight loss), neurological deficits, cardiac anomalies, dermatological findings, renal impairment, and gastrointestinal disturbances. The temporal evolution of symptoms, organ involvement patterns, and response to empirical therapies can offer diagnostic clues. By aggregating and comparing clinical features from multiple cases, CBR facilitates the identification of diagnostic patterns, even when classical textbook criteria are not met, thus supporting individualized clinical reasoning.

Diagnosis

Diagnostic evaluation of rare multisystem disorders necessitates a high index of suspicion, comprehensive history-taking, and systematic use of laboratory and imaging modalities. Multidisciplinary collaboration is often required. Advances in genomics and proteomics have enhanced diagnostic precision, yet interpretation can be challenging without precedent cases. CBR provides a framework for integrating new findings with historical case data, promoting hypothesis generation and prioritizing targeted investigations. Digital repositories and clinical decision-support systems further augment the diagnostic utility of CBR by offering searchable, curated case databases.

Treatment & Management

Management strategies for rare multisystem disorders are typically extrapolated from similar cases due to the scarcity of randomized controlled trials. Therapeutic approaches may include immunosuppression, enzyme replacement, metabolic modulation, or organ-specific supportive care. CBR enables clinicians to evaluate therapeutic responses and adverse effects reported in analogous cases, guiding individualized treatment plans. Multidisciplinary care coordination and patient-centered decision-making remain paramount given the complexity and potential for rapid clinical deterioration.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in targeted therapies, such as biologic agents for autoimmune multisystem diseases and gene therapies for inherited metabolic conditions. The integration of next-generation sequencing and artificial intelligence with CBR has expanded the potential for precision medicine, facilitating earlier diagnosis and more effective interventions. Digital health platforms now enable real-time case sharing and international collaboration, rapidly disseminating emerging evidence and therapeutic innovations.

Guideline Recommendations

Guidelines for rare multisystem diseases frequently acknowledge the limitations of evidence and endorse case-based approaches as adjuncts to formal protocols. Professional societies increasingly recommend the use of case registries, multidisciplinary team reviews, and CBR-supported decision tools to improve diagnostic accuracy and management outcomes. Adherence to consensus guidelines, tempered by insights from relevant cases, optimizes patient care in these complex scenarios.

Conclusion

Rare multisystem clinical presentations demand a nuanced, evidence-informed approach to diagnosis and management. Case-based reasoning, grounded in cumulative clinical experience and facilitated by technological advancements, enhances the clinician's ability to navigate diagnostic ambiguity and therapeutic uncertainty. Continued expansion of curated case databases, integration with emerging technologies, and adoption of CBR in clinical training are essential for improving outcomes in this challenging field.